• How miRNAs Tune Juvenile Hormone Production

  2026-10-21

  A 2025 study in migratory locusts connected stage-specific juvenile hormone levels with vitellogenin expression and ovarian growth, then identified coordinated miRNA–mRNA relationships that may regulate juvenile hormone biosynthetic genes. Its layered evidence supports an upstream post-transcriptional mechanism, while juvenile hormone analog treatment provided downstream endocrine context rather than a direct test of receptor signaling.

• How to Interpret an Anti-EGFL7 Antibody Signal

  2026-10-21

  An anti-EGFL7 antibody identifies EGFL7 as the intended molecular target, but that identity alone does not establish epitope, affinity, specificity, neutralizing activity, or performance in any particular assay. The useful interpretive question is how a molecular recognition event becomes a measured signal—and where that signal can diverge from EGFL7 abundance, localization, or biological activity.

• When Context Changes What GW 4869 Means

  2026-10-20

  The meaning of a result involving GW 4869 depends on the biological model, comparator, readout, and what the intervention can change besides extracellular-vesicle release. In a 2025 lupus nephritis study, GW4869-associated attenuation of glomerular endothelial injury supported a role for podocyte-derived, HMGB1-containing vesicles, but did not by itself establish an exosome-specific mechanism or validate a particular commercial formulation.

• Apoptosis Inducer Kit K2711: Evidence and Scope

  2026-10-19

  APExBIO identifies K2711 as a formulation combining recombinant human TNF-α with the bivalent Smac mimetic SM-164 to promote TNF-α-dependent apoptosis in cultured cells. The product documentation describes expected apoptotic-associated readouts, but provides no identity-matched study, comparative data, effect sizes, or independent validation of pathway specificity or performance across cell types.

• (S)-(+)-Methoprene: Evidence-Bounded Overview

  2026-10-18

  APExBIO describes (S)-(+)-Methoprene as a juvenile hormone analog that activates the insect receptor and transcription factor Methoprene-tolerant (Met), with reported effects on hormone-regulated development and insect metamorphosis. The same product description reports CB1 ligand-binding interference, but no identity-matched paper, assay details, quantitative affinity data, or independent toxicity evidence are available here.

• Ionomycin Calcium Salt: Evidence and Scope

  2026-10-17

  APExBIO describes Ionomycin calcium salt, SKU B5165, as a calcium ionophore that increases intracellular Ca2+ through mobilization of internal calcium pools and promotion of extracellular influx. The product page associates this perturbation with protein synthesis, secretion, inhibition of bladder cancer cell growth, apoptosis-associated readouts, and tumor-growth effects. However, no identity-matched primary paper, effect sizes, sample sizes, or uncertainty estimates are provided here, so the material supports a mechanism-and-scope overview rather than independent claims of efficacy or clinical relevance.

• (S)-(+)-Methoprene: Evidence and Mechanism Scope

  2026-10-16

  (S)-(+)-Methoprene is described by APExBIO as a juvenile hormone analog that activates the insect receptor/transcription factor Methoprene-tolerant (Met), thereby linking receptor signaling to larval-state maintenance and disrupted metamorphosis. The same product description reports CB1 ligand-binding interference, but supplies no identity-matched paper, effect size, comparator, or uncertainty estimate. This article therefore distinguishes documented product claims from research evidence and defines the boundaries for interpreting the compound in arthropod endocrine, receptor-biology, and comparative toxicology contexts.

• (S)-(+)-Methoprene: Mechanism and Evidence Scope

  2026-10-16

  A source-limited overview of (S)-(+)-Methoprene as a juvenile hormone analog, covering its documented identity, the proposed Methoprene-tolerant receptor mechanism, downstream developmental interpretation, reported CB1 binding interaction, and the boundaries created by the absence of an identity-matched research paper.

• FPH1 (BRD-6125): Evidence and Scope

  2026-10-15

  FPH1 (BRD-6125) is described by APExBIO as a small-molecule hepatocyte functional proliferation enhancer associated with increased hepatocyte nuclei count, mitotic activity, albumin secretion, and CYP3A4, alongside reduced AFP in iPS-derived hepatocyte-like cells. However, the supplied evidence is a product description rather than a matched research paper: no molecular target, effect sizes, sample sizes, comparators, uncertainty estimates, or independent validation are provided. The documented scope therefore supports a cautious product and measurement overview, not a confirmed mechanism or demonstrated donor-independent expansion platform.

• Mc-Val-Cit-PABC-PNP: Evidence and Scope

  2026-10-15

  APExBIO describes Mc-Val-Cit-PABC-PNP (SKU B1003) as a cathepsin B-cleavable antibody-drug conjugate peptide linker intended to support lysosomal payload release. The available documentation establishes a supplier-described identity, physicochemical profile, and conceptual mechanism, but it does not provide identity-matched research data, cleavage kinetics, cellular results, comparative efficacy, or clinical validation for this specific material.

• Potassium Phosphate Monobasic: Scope and Evidence

  2026-10-14

  Potassium phosphate monobasic (KH2PO4) is documented by APExBIO as a phosphate reagent for aqueous biochemical buffers and pH control. The available information supports a narrowly defined buffer-related role, but provides no identity-matched research evidence establishing performance in a specific assay, cell system, nucleic-acid formulation, or drying process.

• Cy3 TSA: Evidence, Scope, and Limits

  2026-10-14

  The Cy3 TSA Fluorescence System Kit is described as an HRP-mediated tyramide signal amplification platform for fluorescence-based IHC, ICC, and ISH. Its conceptual value is improved local detectability, but the supplied evidence does not establish assay-specific sensitivity, quantitative linearity, or clinical validity. The related liver-cancer study addresses SIX1-driven lipogenesis and does not document use of this product.

• Dorsomorphin and AMPK Evidence in Alcoholic Steatosis

  2026-10-13

  A 2025 mouse study linked Lactiplantibacillus plantarum P101 with reduced alcohol-associated hepatic lipid accumulation and AMPK-related changes. Pharmacological inhibition with dorsomorphin supported pathway involvement, but the compound’s broader signaling activity and the study’s animal, short-term, and correlational evidence limit causal and clinical interpretation.

• What the 2025 mRNA Protocol Demonstrates

  2026-10-13

  A source-grounded overview of a Nature Protocols workflow for producing and evaluating research-grade mRNA, with emphasis on its conceptual design, reported findings, evidence strength, and limitations. The article also clarifies what the protocol does—and does not—establish about PCR polymerase choice.

• PRC2 Recruitment, Linker DNA and RNA Inhibition

  2026-10-12

  Wang and colleagues used reconstituted human PRC2–nucleosome complexes to examine how DNA, histone features and RNA influence PRC2 recruitment. Their results support a DNA-centered model of nucleosome binding and suggest that RNA can inhibit substrate engagement by competing with linker DNA, while the biochemical system limits direct extrapolation to native chromatin.

8032 records 1/536 page Next 12345 下5页 Last page